Fol. Biol. 2023, 69, 50-58

https://doi.org/10.14712/fb2023069020050

Alarmins and Related Molecules in Elective Surgery

Sabina Strohalmová1,2, Kateřina Levová2, Aleš Antonín Kuběna2, David Hoskovec1, Zdeněk Krška1, Tomáš Zima2, Marta Kalousová2

11st Department of Surgery – Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
2Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic

Received June 2023
Accepted September 2023

References

1. Andersson, U., Tracey, K. J. (2003) HMGB1 in sepsis. Scand. J. Infect Dis. 35, 577-584. <https://doi.org/10.1080/00365540310016286>
2. Antoniou, S. A., Antoniou G. A., Granderath, F. A. et al. (2009) The role of matrix metalloproteinases in the pathogenesis of abdominal wall hernias. Eur. J. Clin. Invest. 39, 953-959. <https://doi.org/10.1111/j.1365-2362.2009.02199.x>
3. Chen, Y. S., Yan, W., Geczy, C. L. et al. (2009) Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res. Ther. 11, R39. <https://doi.org/10.1186/ar2645>
4. Creagh-Brown, B. C., Quinlan, G. J., Hector, L. R. et al. (2013) Association between preoperative plasma sRAGE levels and recovery from cardiac surgery. Mediators Inflamm. 2013, 496031. <https://doi.org/10.1155/2013/496031>
5. Erusalimsky, J. D. (2021) The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. Redox Biol. 42, 101958. <https://doi.org/10.1016/j.redox.2021.101958>
6. Bucova, M., Majernikova, B., Durmanova, V. et al. (2020) HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis. Neurol. Sci. 41, 599-604. <https://doi.org/10.1007/s10072-019-04136-3>
7. Dabbas, N., Adams, K., Pearson, K. et al. (2011) Frequency of abdominal wall hernias: is classical teaching out of date? JRSM Short Rep. 2, 5. <https://doi.org/10.1258/shorts.2010.010071>
8. Danzig, V., Míková, B., Kuchynka, P. et al. (2010) Levels of circulating biomarkers at rest and after exercise in coronary artery disease patients. Physiol. Res. 59, 385-392. <https://doi.org/10.33549/physiolres.931764>
9. de Souza, A., Westra, J., Bijzet, J. et al. (2013) Is serum HMGB1 a biomarker in ANCA-associated vasculitis? Arthritis Res. Ther. 15, R104. <https://doi.org/10.1186/ar4284>
10. Gutt, C., Schläffer, S., Lammert, F. (2020) The treatment of gallstone disease. Dtsch. Arztebl. Int. 117, 148-158.
11. Garrido, M. M., Ribeiro, R. M., Krüger, K. et al. (2021) Relevance of circulating nucleosomes, HMGB1 and sRAGE for prostate cancer diagnosis. In Vivo 35, 2207-2212. <https://doi.org/10.21873/invivo.12492>
12. Hamasaki, M. Y., Barbeiro, H. V., de Souza, H. P. et al. (2014) sRAGE in septic shock: a potential biomarker of mortality. Rev. Bras. Ter. Intensiva 26, 392-396. <https://doi.org/10.5935/0103-507X.20140060>
13. Henriksen, N. A., Yadete, D. H., Sorensen, L. T. et al. (2011) Connective tissue alteration in abdominal wall hernia. Br. J. Surg. 98, 210-219. <https://doi.org/10.1002/bjs.7339>
14. Holub, M., Bartáková, E., Stráníková, A. et al. (2019) Calprotectin and calgranulin C as biomarkers of pancreatic tumors: baseline levels and level changes after surgery. Mediators Inflamm. 2019, 6985703. <https://doi.org/10.1155/2019/6985703>
15. Holzheimer, R. G. (2005) Inguinal hernia: classification, diagnosis and treatment – classic, traumatic and sportsman’s hernia. Eur. J. Med. Res. 10, 121-134.
16. Ibrahim, M., Sarvepalli, S., Morris-Stiff, G. et al. (2018) Gallstones: watch and wait, or intervene? Cleve. Clin. J. Med. 85, 323-331. <https://doi.org/10.3949/ccjm.85a.17035>
17. Jawa, R. S., Anillo, S., Huntoon, K. et al. (2011) Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. J. Intensive Care Med. 26, 73-87. <https://doi.org/10.1177/0885066610384188>
18. Jiang, Z. P., Yang, B., Wen, L. Q. et al. (2015) The etiology of indirect inguinal hernia in adults: congenital or acquired? Hernia 19, 697-701. <https://doi.org/10.1007/s10029-014-1326-5>
19. Jukic, A., Bakiri, L., Wagner, E. F. et al. (2021) Calprotectin: from biomarker to biological function. Gut 70, 1978-1988. <https://doi.org/10.1136/gutjnl-2021-324855>
20. Kalousová, M., Hodková, M., Kazderová, M. et al. (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am. J. Kidney Dis. 47, 406-411. <https://doi.org/10.1053/j.ajkd.2005.12.028>
21. Kalousová, M., Zima, T., Tesar, V. et al. (2005) Advanced glycoxidation end products in chronic diseases – clinical chemistry and genetic background. Mutat. Res. 579, 37-46. <https://doi.org/10.1016/j.mrfmmm.2005.03.024>
22. Kotsiou, O. S., Papagiannis, D., Papadopoulou, R. et al. (2021) Calprotectin in lung diseases. Int. J. Mol. Sci. 22, 106. <https://doi.org/10.3390/ijms22041706>
23. Larsen, N. K., Reilly, M. J., Thankam, F. G. et al. (2019) Novel understanding of high mobility group box-1 in the immunopathogenesis of incisional hernias. Expert Rev. Clin. Immunol. 15, 791-800. <https://doi.org/10.1080/1744666X.2019.1608822>
24. Liang, M. K., Holihan, J. L., Itani, K. et al. (2017) Ventral hernia management: expert consensus guided by systemic review. Ann. Surg. 265, 80-89. <https://doi.org/10.1097/SLA.0000000000001701>
25. Liu, T., Son, M., Diamond, B. (2020) HMGB1 in systemic lupus erythematosus. Front. Immunol. 11, 1057. <https://doi.org/10.3389/fimmu.2020.01057>
26. Liu, Z., Kemp, T. J., Gao, Y. T. et al. (2018) Association of circulating inflammation proteins and gallstone disease. J. Gastroenterol. Hepatol. 33, 1920-1924. <https://doi.org/10.1111/jgh.14265>
27. Moser, B., Bekos, C., Zimprich, F. et al. (2012) The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis. Biochem. Biophys. Res. Commun. 420, 96-101. <https://doi.org/10.1016/j.bbrc.2012.02.121>
28. Ometto, F., Friso, L., Astorri, D. et al. (2017) Calprotectin in rheumatic diseases. Exp. Biol. Med. (Maywood) 242, 859-873. <https://doi.org/10.1177/1535370216681551>
29. Pilzweger, C., Holdenrieder, S. (2015) Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases. Diagnostics (Basel) 5, 219-253. <https://doi.org/10.3390/diagnostics5020219>
30. Sejersen, K., Havelka, A., Sanchez Salaz, P. et al. (2022) Early kinetics of calprotectin in plasma following inguinal hernia surgery. Innate Immun. 28, 49-54. <https://doi.org/10.1177/17534259211069635>
31. Sims, N. A. (2021) Influences of the IL-6 cytokine family on bone structure and function. Cytokine 146, 155655. <https://doi.org/10.1016/j.cyto.2021.155655>
32. Sigley, K., Russo, T., Welch, S. (2020) Umbilical hernia containing appendicitis. Cureus 12, e8075.
33. Skrha, J. Jr., Kalousová, M., Svarcová. J. et al. (2012) Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 120, 277-281.
34. Stoetzer, O. J., Fersching, D. M. I., Salat, C. et al. (2013) Circulating immunogenetic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 34, 81-90. <https://doi.org/10.1007/s13277-012-0513-1>
35. Strohalmová, S., Levová, K., Kuběna, A. A. et al. (2021) The effect of surgery on the levels of matrix metalloproteinases in patients with inguinal hernia. Physiol. Res. 70, 627-634. <https://doi.org/10.33549/physiolres.934625>
36. Tabur, S., Korkmaz, H., Özkaya, M. et al. (2015) Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma. Tumour Biol. 36, 7549-7556. <https://doi.org/10.1007/s13277-015-3468-1>
37. Tanaka, T., Narazaki, M., Kishimoto, T. (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295. <https://doi.org/10.1101/cshperspect.a016295>
38. Tesarova, P., Kalousová, M., Jáchymová, M. et al. (2007) Receptor for advanced glycation end products (RAGE) – soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 25, 720-725. <https://doi.org/10.1080/07357900701560521>
39. Tesarova, P., Kalousová, M., Zima, T. et al. (2016) HMGB1, S100 proteins and other RAGE ligands in cancer – markers, mediators and putative therapeutic targets. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 160, 1-10. <https://doi.org/10.5507/bp.2016.003>
40. Topuz, M. F., Binnetoglu, A., Yumusakhuylu, A. C. et al. (2017) Circulating calprotectin as a biomarker of laryngeal carcinoma. Eur. Arch. Otorhinolaryngol. 274, 2499-2504. <https://doi.org/10.1007/s00405-017-4480-4>
41. Volpin, G., Cohen, M., Assaf, M. et al. (2014) Cytokine levels (IL-4, IL-6, IL-8 and TGFß) as potential biomarkers of systemic inflammatory response in trauma patients. Int. Orthop. 38, 1303-1309. <https://doi.org/10.1007/s00264-013-2261-2>
42. Wu, R., Liu, Y., Yan, R. et al. (2020) Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis. J. Transl. Med. 18, 384. <https://doi.org/10.1186/s12967-020-02556-w>
43. Yamagishi, S., Matsuiu, T., Nakamura, K. (2007) Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr. Drug Targets 8, 1138-1143. <https://doi.org/10.2174/138945007782151298>
44. Yang, D., Han, Z., Oppenheim, J. J. (2017) Alarmins and immunity. Immunol. Rev. 280, 41-56. <https://doi.org/10.1111/imr.12577>
45. Zakiyanov, O., Kalousová, M., Kříha, V. et al. (2011) Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical inflammatory disease. Kidney Blood Press. Res. 34, 457-464. <https://doi.org/10.1159/000329291>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Archive